# Genocury

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genocury

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.genocury.com
- Latest round: Series A (Sep 18, 2025)
- Investors on record: 6

## About

Based in Shenzhen, China, and established in 2021, Genocury is a biotechnology company that focuses on the R&D of f gene and cell therapies for cancers. The core R&D team has experience in the fields of cell therapy and gene therapy. In November 2025, Genocury closed a venture funding from new investor Founton Capital HK Limited.

The company mainly provides gene and cell therapies for tumours. Its products include vivo CAR-T (Chimeric Antigen Receptor T-Cell Therapy) for lymphoma, general NK cellular fluid for blood tumours, and CAR-NK (Chimeric Antigen Receptor NK Cell Therapy) for prostate, ovarian, pancreatic, and lung cancers, based on a gene editing technology platform, and an iPS hematopoietic directional differentiation platform. The in vivo CAR-T therapeutic drugs have completed preclinical development.

The company generates revenue by providing gene and cell therapies for tumours.

## Funding rounds

- Series A, Sep 18, 2025 — OrbiMed Advisors
- Angel, May 15, 2024 — Tianjin Venture Capital
- Angel, Jan 3, 2023 — Shenzhen HTI, Efung Capital, Vinno Capital, Honghui Konggu
- Seed, Feb 21, 2022 — Efung Capital, Vinno Capital

## Investors

- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Seed, Angel
- Vinno Capital (https://capitalatlas.ai/funds/vinno-capital) — Seed, Angel
- Shenzhen HTI (https://capitalatlas.ai/funds/shenzhen-hti) — Angel
- Honghui Konggu — Angel
- Tianjin Venture Capital (https://capitalatlas.ai/funds/tianjin-venture-capital) — Angel
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A